ArticleMedicine2026
Association between lactate-to-albumin ratio and all-cause mortality in critically ill hepatic failure patients with sepsis: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Hepatic failure complicated by sepsis is a highly lethal condition with an extremely high fatality rate. The lactate-to-albumin ratio (LAR) has been identified as a predictor of adverse outcomes in various diseases. However, the prognostic value of LAR in critically ill hepatic failure patients with sepsis remains to be defined. Participants were selected from the Medical Information Mart for Intensive Care-IV database and categorized into tertiles according to the LAR index. The primary outcomes were 30-day and 365-day all-cause mortality. Kaplan-Meier survival analysis was performed to visualize survival differences across tertiles. Cox proportional hazards regression and restricted cubic spline (RCS) models were employed to characterize the relationship between the LAR index and all-cause mortality; subgroup analyses were conducted to explore potential interactions. A total of 1346 patients were included; all-cause mortality rates at 30, 90, 180, and 365 days were 43.16%, 53.05%, 55.72%, and 58.99%, respectively. Kaplan-Meier curves confirmed that survival at 30, 90, 180, and 365 days decreased significantly across increasing LAR tertiles. Adjusted multivariable Cox regression showed that, compared with the lowest tertile, the highest LAR tertile had an 84% higher 30-day mortality risk (hazard ratio [HR] = 1.84; 95% confidence interval [CI]: 1.43-2.36; P < .001) and a 63% higher 365-day mortality risk (HR = 1.63; 95% CI: 1.32-2.01; P < .001). RCS analysis verified a positive, nonlinear association between the LAR index and all-cause mortality at 30, 90, 180, and 365 days (all nonlinear P < .001). Subgroup analysis indicated a stronger association between LAR and mortality in non-elderly patients. In critically ill hepatic failure patients with sepsis, elevated LAR is independently associated with increased all-cause mortality. This highlights the potential of LAR as a key prognostic biomarker for risk stratification and management of hepatic failure patients with sepsis in the intensive care unit.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.